These stories show how our momentum of discovery is changing the lives of cancer patients.
BCL-2 INHIBITORS
Identifying BCL-2 as a protein that cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, a powerful agent against CLL and AML.
PD-L1 AND CTLA-4 PATHWAYS
Combining treatments of PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.
NOBEL PRIZE WINNING RESEARCH
Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.
CDK4/6 INHIBITORS
CDK4/6 inhibitors can block the proteins that cause breast cancer cells to multiply faster, leading to higher survival rates for many advanced breast cancers.
PROTEIN DEGRADATION
Protein degradation can target cancer-causing proteins and selectively destroy them right inside the cell, making a difference in multiple myeloma and other blood cancers.
Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.
